New leadership role focuses on immunology and global innovation efforts.
- Dr. Jenny Xie joins as Chief Scientific Officer
- Focus on strengthening immunology expertise
- Role includes overseeing global innovation efforts
Harbour Biomed, a biotechnology company, has appointed Dr. Jenny Xie as its Chief Scientific Officer, specializing in immunology. In her new role, Dr. Xie will also lead the company's global external innovation initiatives. This strategic hire aims to enhance the organization's capabilities in developing innovative therapeutic solutions.
Dr. Xie brings extensive experience in immunology and drug development, having worked in various leadership roles across multiple companies. With her expertise, Harbour Biomed plans to bolster its research and development efforts, specifically in immunology-related therapies. The company aims to leverage her background to identify and integrate external innovations that align with its mission.
Dr. Xie's appointment marks a significant step for Harbour Biomed as it seeks to enhance its scientific leadership. The company is focused on expanding its product pipeline and advancing its research programs, particularly in the field of immunology, to meet growing healthcare needs.
